Real-world Study to Assess Adherence to IOP Lowering Therapy in Patients With Glaucoma or Ocular Hypertension Using CONNECTDROP®

Real-world Study to Assess Adherence to IOP Lowering Therapy in Patients With Glaucoma or Ocular Hypertension Using CONNECTDROP®: the GRANITE Study (Glaucoma tReatment AdhereNce wIth connecTed dEvice in Italy)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07206628

Enrollment

200

Registered

2025-10-03

Start date

2025-09-19

Completion date

2027-09-01

Last updated

2026-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adherence to Glaucoma Therapy

Brief summary

The goal of this real-life, national, multicentre, prospective clinical investigation is to describe the adherence rate over time in patients with glaucoma or OHT already treated with IOP-lowering eye drops using connected device CONNECTDROP® The main questions it aims to answer are: * The mean annual adherence rate, defined as the percentage of the prescribed doses taken by the patient * The adherence profile of each patient * The association between the adherence profile, the objective adherence data and the clinical data. Participants will use the connected device CONNECTDROP® associated with the smartphone application on a daily basis.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult patient (≥ 18 years old), man or woman * Patient with a diagnosis of bilateral open angle glaucoma or OHT * Patients being prescribed with glaucoma eye drops in EASYGRIP® bottle for at least 6 weeks in monotherapy. * Patient willing to participate in the study * Patient who consents for data collection in the frame of the study

Exclusion criteria

* Pregnant and/or lactating woman * Patient receiving another ocular treatment for a chronic condition (i.e. regular instillations for several months) * Protected patient: adult under guardianship, curatorship or other protection legal, deprived of liberty by judicial or administrative decision

Design outcomes

Primary

Measure	Time frame	Description
Adherence rate over time in patients with glaucoma or OHT already treated with IOP-lowering eye drops in EASYGRIP® bottle clipped with CONNECTDROP®	From enrollment to the end of the study at 12 months	Assessment of the mean annual adherence rate, defined as the percentage of the prescribed doses actually taken by the patient (i.e. at least 2 instillations per day).

Countries

Italy

Contacts

CONTACTMedical Operation Manager

Fabienne.HESKIA@theapharma.com+33 4 73 98 14 36

Outcome results